Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Treatment of Chronic Idiopathic Myelofibrosis
Videos
Treatment of Chronic Idiopathic Myelofibrosis
05/08/2020
Ruben Mesa, MD, FACP, provides an update on therapy options for the treatment of chronic idiopathic myelofibrosis. 
Ruben Mesa, MD, FACP, provides an update on therapy options for the treatment of chronic idiopathic myelofibrosis. 
Ruben Mesa, MD, FACP, provides...
05/08/2020
Oncology
Approaching MRD in Multiple Myeloma
Videos
Approaching MRD in Multiple Myeloma
05/07/2020
Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.
Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.
Thomas Martin, MD, discusses the...
05/07/2020
Oncology
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
Videos
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
04/24/2020
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the...
04/24/2020
Oncology
Who Should Receive CAR-T Therapy for Lymphoma?
Videos
Who Should Receive CAR-T Therapy for Lymphoma?
03/25/2020
Lauren Pinter-Brown, MD, FACP, explains which patients with lymphoma should be referred to receive CAR T-cell therapy. 
Lauren Pinter-Brown, MD, FACP, explains which patients with lymphoma should be referred to receive CAR T-cell therapy. 
Lauren Pinter-Brown, MD,...
03/25/2020
Oncology
What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?
Videos
What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?
03/11/2020
Elizabeth Brem, MD, argues in favor of chemotherapy and or stem cell transplant-based regimens to treat relapsed/refractory FL.
Elizabeth Brem, MD, argues in favor of chemotherapy and or stem cell transplant-based regimens to treat relapsed/refractory FL.
Elizabeth Brem, MD, argues in...
03/11/2020
Oncology
Treatment Approaches in Systemic Marginal Zone Lymphoma
Videos
Treatment Approaches in Systemic Marginal Zone Lymphoma
03/07/2020
Elizabeth Brem, MD, gives an overview of current treatment options for MZL.
Elizabeth Brem, MD, gives an overview of current treatment options for MZL.
Elizabeth Brem, MD, gives an...
03/07/2020
Oncology
Novel Therapeutic Approaches in CLL
Videos
Novel Therapeutic Approaches in CLL
03/07/2020
Michael Choi, MD, discusses novel approaches for the treatment of patients with CLL.
Michael Choi, MD, discusses novel approaches for the treatment of patients with CLL.
Michael Choi, MD, discusses...
03/07/2020
Oncology
Emerging Therapies for Relapsed/Refractory MM
Videos
Emerging Therapies for Relapsed/Refractory MM
03/07/2020
Thomas Martin, MD, discusses emerging treatment options for patients with relapsed/refractory MM.
Thomas Martin, MD, discusses emerging treatment options for patients with relapsed/refractory MM.
Thomas Martin, MD, discusses...
03/07/2020
Oncology
New Approaches to Upfront Treatment of MCL
Videos
New Approaches to Upfront Treatment of MCL
03/07/2020
Kami Maddocks, MD, talks about what’s new in the upfront treatment landscape for MCL.
Kami Maddocks, MD, talks about what’s new in the upfront treatment landscape for MCL.
Kami Maddocks, MD, talks about...
03/07/2020
Oncology
Treating Smoldering Myeloma: Watch and Wait or Early Intervention?
Videos
Treating Smoldering Myeloma: Watch and Wait or Early Intervention?
03/07/2020
Peter Voorhees, MD, argues in favor of early intervention when treating patients with smoldering myeloma.
Peter Voorhees, MD, argues in favor of early intervention when treating patients with smoldering myeloma.
Peter Voorhees, MD, argues in...
03/07/2020
Oncology

Advertisement

About

At Great Debates and Updates in Hematologic Malignancies, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of hematology and oncology.

Through comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Platinum Sponsors

johnson & johnson

 

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use